ARCUTIS BIOTHERAPEUTICS INC

Arcutis insider sales: Matsuda Masaru sells 3,674 shares at $25, reflecting steady 10‑b‑5‑1 plan execution amid strong stock gains and pipeline momentum.

Welgus Howard G’s September insider buys in Arcutis Biotherapeutics signal confidence, with a net 2,092‑share purchase amid a 13% weekly rally and a 52‑week high, hinting at potential upside if the pipeline delivers.

Arcutis insider sale of 9,989 shares at $25.03 shows a planned 10‑b‑5‑1 liquidity move, not a panic; the company’s strong fundamentals and pipeline keep long‑term growth intact.

Arcutis insider trading shows routine RSU tax moves, not a sell‑off. 1,700 shares sold by CMO Patrick Burnett at $27—no crisis, steady fundamentals and a promising pipeline remain.

Arcutis insider Welgus Howard G. buys shares below market and sells options, signaling confidence in its immunotherapy pipeline and potential upside.

Arcutis insider Patrick Burnett buys shares at $3.64, signaling confidence that the stock is undervalued amid a modest decline and a solid pipeline.

ARCUTIS insider sale: CEO Todd Watanabe sold 4,375 shares on Aug 3, 2026 for $26.12—routine liquidity, not a red flag for investors.

Arcutis Biotherapeutics adds Christopher Peetz to its board, sparking insider buying that signals confidence in its inflammatory skin pipeline and upcoming Q2 earnings.

Arcutis insider buying shows board confidence in its biopharma pipeline—but investors must watch clinical milestones and market reaction.

Arcutis CFO sells 435 shares amid a 10% stock drop; insider selling signals cautious confidence and may signal future restructuring.